Press Release

Mycotoxin testing and feed binders: a USD 3.28 billion market where the test is priced like a commodity and the binder is priced like insurance

· Food & Beverages

LONDON — 21 November 2026. The global market for mycotoxin testing and feed mycotoxin binders was worth USD 3.28 billion in 2025 and will reach USD 5.80 billion by 2033, a compound annual growth rate of 7.39 per cent, according to a new report from Pheonix Research. The report finds that the two halves of the market behave in almost opposite ways, and that the divergence is created by regulation rather than by competition.

Mycotoxin testing accounted for USD 1.42 billion of the 2025 market and grows at 7.00 per cent to USD 2.44 billion. Feed mycotoxin binders accounted for USD 1.86 billion and grow at 7.67 per cent to USD 3.36 billion. Of the USD 2.52 billion of growth between the two dates, USD 1.81 billion — 71.7 per cent — comes from more volume and USD 0.71 billion from price and mix.

That aggregate conceals the finding. Testing derives 89.9 per cent of its growth from volume and only 10.1 per cent from price: the realised value of a single test moves from USD 14.79 to USD 15.44 across eight years, a rise of 0.54 per cent a year. Binders derive 59.3 per cent of their growth from volume and 40.7 per cent from price and mix, with the realised price of a tonne rising from USD 5,812 to USD 7,104 — 2.54 per cent a year.

“A mycotoxin test is anchored to a published reference method, so the reagent is comparable and the price converges,” the report finds. “A binder is not anchored to anything comparable. When the European Food Safety Authority assessed a bentonite-and-sepolite preparation for all animal species in 2013, it concluded the product was safe up to 20,000 mg/kg of complete feed and that there was insufficient evidence to conclude on its efficacy. Safety was established. The claim was not. That single asymmetry is worth roughly 175 basis points of compound growth to this market.”

The report argues that the demand engine is the shape of the regulatory limits. Under the US Food and Drug Administration’s Compliance Policy Guide Sec. 683.100, aflatoxin in corn and peanut products intended for finishing beef cattle is permitted to 300 parts per billion, while the same toxin in feed for dairy animals or for unspecified use is permitted to 20 parts per billion — a fifteen-fold spread on one molecule, set by the species rather than by the toxin.

Because the limit depends on destination, a lot that fails a food specification does not disappear: it is declassified to feed, where the binder makes it usable. COCERAL, presenting its mycotoxin management report to an EFSA standing group in June 2025, identified exactly that as a future constraint — a growing share of food-grade grain being downgraded to feed as food limits are missed, and in the worst case some corn failing the limits set for feed material as well. “The test is the gate and the binder is the toll,” the report states. “Every declassification event creates binder demand.”

The ownership record is presented as a test of the thesis. Royal DSM acquired Erber Group — Biomin for mycotoxin risk management and Romer Labs for food and feed safety diagnostics — for an enterprise value of EUR 980 million in October 2020. In June 2025 it sold its 50 per cent stake in the Feed Enzymes Alliance to Novonesis for EUR 1.5 billion, and in February 2026 dsm-firmenich agreed to sell the remaining Animal Nutrition & Health business to CVC Capital Partners at an enterprise value of about EUR 2.2 billion, against approximately EUR 3.5 billion of net sales and around EUR 0.5 billion of Adjusted EBITDA in 2025.

Notes on method. The value base is a Pheonix construct, not a reported figure: no company in this market discloses a clean mycotoxin-testing line or a clean binder line, and the plausible range around the USD 3.28 billion base is USD 2.95 billion to USD 3.65 billion. The only auditable disclosure in the category, Neogen’s Natural Toxins & Allergens line at USD 77.5 million, bundles mycotoxins with allergens and is not split. The volume line covers tests; binder tonnage is modelled separately and is not included in the published unit figure. Pheonix has not published a regional split for this market, because the model carries no geography, and does not infer one from secondary commentary.

The report follows Pheonix’s 70/30 convention, with approximately 70 per cent of evidential weight from secondary sources — regulator publications, official action levels, company disclosures and the scientific literature — and 30 per cent from Pheonix’s own analysis, including the market construct, the volume and price decomposition, the species-differentiation reading of the action levels and a programme of open-ended interviews with suppliers, laboratory managers and mill nutritionists.

Global Mycotoxin Testing & Feed Binder Market Report, Size, Share and Forecast 2026–2033 is published in the Food Safety & Quality Testing segment of Pheonix Research.